Characteristics | Number of patients | Percentage |
---|---|---|
Patients treated | 29 | - |
Age | ||
Median | 57 | - |
Range | 35–72 | - |
Gender | ||
Male | 21 | 72.4 |
Female | 8 | 27.6 |
Histological subtype | ||
Squamous carcinoma | 11 | 37.9 |
Adenocarcinoma | 18 | 62.1 |
Stage | ||
IIIa (T2N2M0/T3N2M0) | 12 (8/4) | 41.4 |
IIIb (T2N3M0/T4N1M0/T4N2M0) | 17 (2/8/7) | 58.6 |
ECOG performance status | ||
0 | 12 | 41.4 |
1 | 12 | 41.4 |
2 | 5 | 17.2 |
Prior chemotherapy (cycles) | ||
Gemcitabine and cisplatin | 14 (46) | 48.3% |
Vinorelbine and cisplatin | 8 (21) | 27.6% |
Paclitaxel and cisplatin | 7 (26) | 24.1% |
Prior radiotherapy | 11 | 37.9% |